Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebrocurin is a peptide-based neuroprotective drug developed and manufactured in Ukraine by the Scientific-Research Institute (NIR) of Molecular Medicine. It consists of a complex of low-molecular-weight neuropeptides and amino acids derived from bovine embryo brain tissue. The drug is primarily indicated for the treatment of organic brain lesions, including ischemic stroke, traumatic brain injury, and cognitive disorders such as dementia and developmental delays in children. Its mechanism of action involves the modulation of endogenous neuroprotective pathways, specifically increasing the expression of heat shock proteins (HSP70) and hypoxia-inducible factors (HIF-1α, HIF-3α). These actions help stabilize cell membranes, inhibit apoptosis, and promote neuroplasticity and functional recovery of the central nervous system. It is often compared to other cerebroprotectors like Cerebrolysin but is distinguished by its embryonic source material.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cerebrocurin.